Evidence map›Paper›PMID 38937498›Full record

ArticleScientific reports2024

Evaluating the low-rank coal degradation efficiency bioaugmented with activated sludge.

Marzhan Kozhakhmetova, Nuraly Akimbekov, Ilya Digel, Kuanysh Tastambek

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marzhan KozhakhmetovaAl-Farabi Kazakh National University, 050040, Almaty, Kazakhstan. marzhanur.7@mail.ru.
Nuraly AkimbekovAl-Farabi Kazakh National University, 050040, Almaty, Kazakhstan.
Ilya DigelAachen University of Applied Sciences, Heinrich-Mussmann-Straße 1, 52428, Jülich, Germany.
Kuanysh TastambekAl-Farabi Kazakh National University, 050040, Almaty, Kazakhstan.

Funding

Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan AP19677705
6 · The paper itself

Abstract

Microbial bioaugmentation of coal is considered as a viable and ecologically sustainable approach for the utilization of low-rank coals (LRC). The search for novel techniques to derive high-value products from LRC is currently of great importance. In response to this demand, endeavors have been undertaken to develop microbially based coal solubilization and degradation techniques. The impact of supplementing activated sludge (AS) as a microbial augmentation to enhance LRC biodegradation was investigated in this study. The LRC and their biodegradation products were characterized using the following methods: excitation-emission Matrices detected fluorophores at specific wavelength positions (O, E, and K peaks), revealing the presence of organic complexes with humic properties. FTIR indicated the increased amount of carboxyl groups in the bioaugmented coals, likely due to aerobic oxidation of peripheral non-aromatic structural components of coal. The bacterial communities of LRC samples are primarily composed of Actinobacteria (up to 36.2%) and Proteobacteria (up to 25.8%), whereas the Firmicutes (63.04%) was the most abundant phylum for AS. The community-level physiological profile analysis showed that the microbial community AS had high metabolic activity of compared to those of coal. Overall, the results demonstrated successful stimulation of LRC transformation through supplementation of exogenous microflora in the form of AS.

Indexed as

Biodegradation, EnvironmentalCoalSewageActinobacteriaBacteriaProteobacteriaSpectroscopy, Fourier Transform InfraredCoalSewageActivated sludgeBiodegradationHumic-like compoundsLow-rank coalMicrobial community

Identifiers

PMID38937498
PMCPMC11211346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.